Asston Pharmaceuticals Ltd
Asston Pharmaceuticals Ltd (APL) last reported results for the quarter ended Mar 2026, with sales of ₹10.05 crore and net profit of ₹0.48 crore. Asston Pharmaceuticals Ltd’s board meets on 13 Oct 2026. The stock last traded at ₹94, a market capitalisation of ₹103 crore, on a P/E of 26.2. Over the past 52 weeks the stock has ranged between ₹60 and ₹126. Figures are as of 6 Oct 2026 and are not real time.
Asston Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹94
- Market cap
- ₹103 cr
- Stock P/E
- 26.2
- Book value
- ₹45.6
- ROE
- 15.7%
- ROCE
- 17.0%
- Dividend yield
- 0.00%
- 52w high / low
- 126/60.0
Metrics as of 6 Oct 2026. Not real time.
Track Asston Pharmaceuticals Ltd
Cruxal reads every Asston Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Asston Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 57%
- TTM
- 2%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 55%
- TTM
- 4%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- -2%
- 10 Years
- %
- 5 Years
- 28%
- 3 Years
- 26%
- Last Year
- 16%
Asston Pharmaceuticals Ltd quarterly results
| ₹ crore | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 15.97 | 9.07 | 15.42 | 10.05 |
| Expenses | 13.71 | 5.89 | 13.19 | 12.85 |
| Operating profit | 2.26 | 3.18 | 2.23 | -2.8 |
| OPM % | 14.15% | 35.06% | 14.46% | -27.86% |
| Other income | 0.64 | -0.07 | -1.86 | 4.63 |
| Interest | 0.42 | 0.53 | 0.28 | 0.36 |
| Depreciation | 0.02 | 0.02 | 0.07 | 0.25 |
| Profit before tax | 2.46 | 2.56 | 0.02 | 1.22 |
| Tax % | 22.76% | 23.44% | -50.00% | 59.84% |
| Net profit | 1.9 | 1.95 | 0.03 | 0.48 |
| EPS (₹) | 24.24 | 3.11 | 0.04 | 0.56 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Asston Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 9.6 | 6.54 | 16.03 | 25.04 | 25.47 |
| Operating profit | -0.36 | 1.52 | 3.82 | 5.44 | -0.52 |
| OPM % | -3.75% | 23.24% | 23.83% | 21.73% | -2.04% |
| Net profit | 0.11 | 1.06 | 2.43 | 3.85 | 3.87 |
| EPS (₹) | 1.57 | 15.14 | 31.00 | 6.14 | 4.55 |
TTM is the trailing twelve months to the most recent quarter.
Asston Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 0.70 | 0.70 | 0.78 | 6.27 | 8.51 |
| Reserves | 0.23 | 1.29 | 6.40 | 4.76 | 30.35 |
| Borrowings | 3.31 | 5.24 | 6.82 | 7.26 | 5.10 |
| Other liabilities | 5.25 | 6.46 | 6.70 | 9.83 | 7.69 |
| Total liabilities | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
| Fixed assets | 0.92 | 1.13 | 0.97 | 0.96 | 10.69 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 8.57 | 12.56 | 19.73 | 27.16 | 40.96 |
| Total assets | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
As reported by the company. Total assets equal total liabilities by construction.
Asston Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | -1.19 | -0.32 | -3.97 | -0.03 | -10.18 |
| Cash from investing | 0.00 | -0.91 | -0.01 | 0.73 | -9.91 |
| Cash from financing | 1.29 | 1.21 | 3.86 | -0.51 | 21.18 |
| Net cash flow | 0.10 | -0.01 | -0.12 | 0.19 | 1.09 |
| Free cash flow | -1.19 | -0.57 | -3.98 | 0.68 | -20.24 |
| CFO / operating profit | 322% | -20% | -92% | -0% | 1,500% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Asston Pharmaceuticals Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | 37.14% | 37.78% | 36.61% | 16.96% |
| Debtor days | 243.33 | 480.53 | 380.71 | 357.86 | 524.07 |
| Inventory days | 27.24 | 204.29 | 53.91 | 18.59 | 16.14 |
| Days payable | 246.78 | 754.51 | 217.50 | 156.94 | 120.76 |
| Cash conversion cycle | 23.79 | -69.70 | 217.12 | 219.50 | 419.45 |
| Working capital days | -12.17 | 43.53 | 162.80 | 176.96 | 434.22 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Asston Pharmaceuticals Ltd shareholding pattern
Promoters held 50.66% at Apr 2026, broadly unchanged since Sep 2025. FIIs 0.00%.
| % held | Sep 2025 | Mar 2026 | Apr 2026 |
|---|---|---|---|
| Promoters | 50.66% | 50.66% | 50.66% |
| FIIs | 6.04% | 1.91% | 0.00% |
| Public | 43.30% | 47.41% | 49.35% |
| No. of shareholders | 751 | 687 | 661 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When does Asston Pharmaceuticals Ltd’s board next meet?
Asston Pharmaceuticals Ltd’s board meets on 13 Oct 2026.
- Board meetingConsider and approve shifting of registered office and acquisition of immovable property
See the full results calendar for every Indian company reporting in the next 30 days.
Asston Pharmaceuticals Ltd corporate filings
- Asston Pharmaceuticals to Hold Board Meeting on 13th October 2026 to Consider Property Acquisition and Office ShiftBoard Meetinglow impact
Cruxal's analysis: Asston Pharmaceuticals Limited has announced a board meeting scheduled for 13th October…
Read the full analysis - Asston Pharmaceuticals Approves Financials and Management Reappointments in 2026 AGMCompany Updatelow impact
Cruxal's analysis: Asston Pharmaceuticals has received shareholder approval for its audited standalone…
Read the full analysis - Annual General Meeting (AGM) Scrutinizer Reports Reveal No Major Shareholder Movements or Resolutions PassedAGM/EGMlow impact
Cruxal's analysis: The company, Asston Pharmaceuticals Limited, held its 7th AGM on 29th September 2026 via…
Read the full analysis - Asston Pharmaceuticals Limited concludes 7th Annual General Meeting; shareholders to vote on key management remuneration increasesAGM/EGMlow impact
Cruxal's analysis: Asston Pharmaceuticals Limited held its 7th Annual General Meeting on 29th September…
Read the full analysis - Trading Window ClosureInsider Trading / SASTlow impact
- Asston Pharmaceuticals Ltd releases 7th Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Asston Pharmaceuticals has filed its 7th Annual Report for the financial year 2025-26…
Read the full analysis - Asston Pharmaceuticals Limited announces 7th Annual General Meeting (AGM) for September 29, 2026, with proposals for managerial remuneration revisionsAGM/EGMlow impact
Cruxal's analysis: Asston Pharmaceuticals Limited has issued a notice for its 7th Annual General Meeting to…
Read the full analysis - Asston Pharmaceuticals Limited Announces Preferential Allotment of 24.10 Lakh Equity Shares at INR 115 per ShareOthersmedium impact
Cruxal's analysis: Asston Pharmaceuticals Limited has approved the preferential allotment of 24.10 lakh…
Read the full analysis - Prakruti R Pali increases stake in Asston Pharmaceuticals Limited to 9.03% via open market acquisitionInsider Trading / SASTlow impact
Cruxal's analysis: Asston Pharmaceuticals Limited has reported that non-promoter investor Prakruti R Pali…
Read the full analysis - Prakruti R Pali increases stake in Asston Pharmaceuticals Limited to 7.26% via open market acquisitionInsider Trading / SASTmedium impact
Cruxal's analysis: Asston Pharmaceuticals Limited has reported that investor Prakruti R Pali has increased…
Read the full analysis - Asston Pharmaceuticals Limited: Non-promoter Prakruti R Pali increases stake to 5.33% via open market acquisitionInsider Trading / SASTlow impact
Cruxal's analysis: Asston Pharmaceuticals Limited has disclosed that Mrs. Prakruti R Pali, a non-promoter…
Read the full analysis - Asston Pharmaceuticals Limited: Non-promoter Prakruti R Pali increases stake to 5.33% via open market purchaseInsider Trading / SASTlow impact
Cruxal's analysis: Asston Pharmaceuticals Limited has disclosed that Prakruti R Pali, a non-promoter entity…
Read the full analysis - Asston Pharmaceuticals Limited schedules Board Meeting for September 4, 2026, to discuss auditor appointment and executive remunerationBoard Meetinglow impact
Cruxal's analysis: Asston Pharmaceuticals Limited has announced a Board Meeting scheduled for September 4…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.